Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 11, 2020
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy toolsLorenzo Gerratana, Andrew A Davis, Maurizio Polano, et al.
Experimental Hematology & Oncology|May 6, 2025
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneityTania Rossi, Sara Bandini, Michele Zanoni, et al.
Critical Reviews in Oncology/Hematology|October 18, 2022
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approachCaterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 26, 2021
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancerAriana Soledad Poetto, Bianca Posocco, Sara Gagno, et al.
Oncotarget|January 20, 2018
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Massimo Di Maio, Anna Crispo, et al.
Breast (Edinburgh, Scotland)|April 22, 2018
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) surveyMarta Bonotto, Debora Basile, Lorenzo Gerratana, et al.
Therapeutic Advances in Medical Oncology|December 5, 2019
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLCMarika Cinausero, Noemi Laprovitera, Giovanna De Maglio, et al.
Cancers|June 27, 2019
Role of Bruton's Tyrosine Kinase in Stage III Colorectal CancerDebora Basile, Lorenzo Gerratana, Angela Buonadonna, et al.
Frontiers in Oncology|October 19, 2020
Plasma-Based Longitudinal Evaluation of <i>ESR1</i> Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerLorenzo Gerratana, Debora Basile, Alessandra Franzoni, et al.
Clinical Breast Cancer|January 9, 2023
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain MetastasesAmi N Shah, Cesar A Santa-Maria, Dhruvika Mukhija, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|December 11, 2020
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy toolsLorenzo Gerratana, Andrew A Davis, Maurizio Polano, et al.
Experimental Hematology & Oncology|May 6, 2025
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneityTania Rossi, Sara Bandini, Michele Zanoni, et al.
Critical Reviews in Oncology/Hematology|October 18, 2022
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approachCaterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 26, 2021
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancerAriana Soledad Poetto, Bianca Posocco, Sara Gagno, et al.
Oncotarget|January 20, 2018
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Massimo Di Maio, Anna Crispo, et al.
Breast (Edinburgh, Scotland)|April 22, 2018
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) surveyMarta Bonotto, Debora Basile, Lorenzo Gerratana, et al.
Therapeutic Advances in Medical Oncology|December 5, 2019
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLCMarika Cinausero, Noemi Laprovitera, Giovanna De Maglio, et al.
Cancers|June 27, 2019
Role of Bruton's Tyrosine Kinase in Stage III Colorectal CancerDebora Basile, Lorenzo Gerratana, Angela Buonadonna, et al.
Frontiers in Oncology|October 19, 2020
Plasma-Based Longitudinal Evaluation of <i>ESR1</i> Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerLorenzo Gerratana, Debora Basile, Alessandra Franzoni, et al.
Clinical Breast Cancer|January 9, 2023
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain MetastasesAmi N Shah, Cesar A Santa-Maria, Dhruvika Mukhija, et al.
Pageof 13